Investment Analysts’ Weekly Ratings Changes for Alkermes (ALKS)

Several analysts have recently updated their ratings and price targets for Alkermes (NASDAQ: ALKS):

• 2/14/2025 – Alkermes had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 2/13/2025 – Alkermes was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 2/13/2025 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
• 2/11/2025 – Alkermes is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $40.00 price target on the stock.

Alkermes Stock Performance

Shares of Alkermes stock opened at $35.52 on Tuesday. The stock has a market capitalization of $5.78 billion, a PE ratio of 16.37, a price-to-earnings-growth ratio of 2.20 and a beta of 0.49. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.45. The stock has a 50 day moving average price of $30.99 and a two-hundred day moving average price of $29.16.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Research analysts forecast that Alkermes plc will post 1.31 EPS for the current year.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 9,221 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $31.50, for a total value of $290,461.50. Following the completion of the sale, the executive vice president now directly owns 59,730 shares of the company’s stock, valued at $1,881,495. This represents a 13.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Cato T. Laurencin sold 2,691 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the transaction, the director now owns 23,013 shares in the company, valued at $732,964.05. This represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 323,608 shares of company stock worth $10,854,725 over the last three months. 4.89% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alkermes

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Venturi Wealth Management LLC purchased a new position in Alkermes during the 4th quarter worth $25,000. EverSource Wealth Advisors LLC boosted its holdings in Alkermes by 106.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock worth $47,000 after purchasing an additional 842 shares during the last quarter. Blue Trust Inc. grew its position in Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock worth $49,000 after purchasing an additional 1,629 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Alkermes by 558.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock valued at $85,000 after buying an additional 2,502 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in Alkermes in the 4th quarter valued at about $98,000. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.